Skip to main content
Erschienen in:

01.05.2005 | Leitthema

Immuntherapie urologischer Tumoren

verfasst von: Dr. C. Doehn, I. Kausch, D. Jocham

Erschienen in: Die Onkologie | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die 3 häufigsten urologischen Malignome sind das Prostatakarzinom, das Harnblasenkarzinom und das Nierenzellkarzinom. Das mittlere Alter bei Diagnose liegt in vielen Fällen zwischen 60 und 70 Jahren. Alle 3 Malignome sind bei organbegrenztem Wachstum prinzipiell durch eine operative Therapie heilbar. Bei Vorliegen von Metastasen wird die Prognose deutlich schlechter und liegt hinsichtlich des mittleren Überlebens bei 5 Jahren für das Prostatakarzinom bzw. 12–15 Monaten für das Harnblasenkarzinom und das Nierenzellkarzinom.
Immuntherapien urologischer Tumoren sind weit verbreitet. So gehören die unspezifische Therapie mittels BCG beim Harnblasenkarzinom bzw. die Zytokintherapie mittels Interferon-α und/oder Interleukin-2 beim Nierenzellkarzinom zum Standard. Andere Verfahren wie die Antikörper- oder Vakzinetherapie sind oder werden in Phase-III-Studien untersucht.
In folgender Übersichtsarbeit werden Ergebnisse zur Immuntherapie des Prostatakarzinoms, Harnblasenkarzinoms und Nierenzellkarzinoms vorgestellt.
Literatur
1.
Zurück zum Zitat Atzpodien J, Kirchner H, Jonas U et al. (2004) Prospectively Randomized Study of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188–1194PubMed Atzpodien J, Kirchner H, Jonas U et al. (2004) Prospectively Randomized Study of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188–1194PubMed
2.
Zurück zum Zitat de Boer EC, De Reijke TM, Vos PC et al. (2000) Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guerin as therapy for superficial bladder cancer: a comparative study. Clin Infect Dis [Suppl] 3:109–114CrossRef de Boer EC, De Reijke TM, Vos PC et al. (2000) Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guerin as therapy for superficial bladder cancer: a comparative study. Clin Infect Dis [Suppl] 3:109–114CrossRef
3.
Zurück zum Zitat Den Otter W, Dobrowolski Z, Bugajski A et al. (1998) Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 159:1183–1186CrossRefPubMed Den Otter W, Dobrowolski Z, Bugajski A et al. (1998) Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 159:1183–1186CrossRefPubMed
4.
Zurück zum Zitat Böhle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90–95PubMed Böhle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90–95PubMed
5.
Zurück zum Zitat Brenner H (2002) Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360:1131–1135CrossRefPubMed Brenner H (2002) Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360:1131–1135CrossRefPubMed
6.
Zurück zum Zitat Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC et al. (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21:679–689CrossRefPubMed Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC et al. (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21:679–689CrossRefPubMed
7.
Zurück zum Zitat Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L et al. (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21:3133–3140CrossRefPubMed Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L et al. (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21:3133–3140CrossRefPubMed
8.
Zurück zum Zitat Coppin C, Porzolt F, Kumpf J, Coldman A, Wilt T (2000) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 3: CD001425PubMed Coppin C, Porzolt F, Kumpf J, Coldman A, Wilt T (2000) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 3: CD001425PubMed
9.
Zurück zum Zitat Doehn C, Kausch I, Melz S, Behm A, Jocham D (2004a) Cytokine and vaccine therapy of kidney cancer. Exp Rev Anticancer Ther 4:1097–1111CrossRef Doehn C, Kausch I, Melz S, Behm A, Jocham D (2004a) Cytokine and vaccine therapy of kidney cancer. Exp Rev Anticancer Ther 4:1097–1111CrossRef
10.
Zurück zum Zitat Doehn C, Jocham D (2004b) Vaccination immunotherapy-an update. Scand J Surg 93:163–169PubMed Doehn C, Jocham D (2004b) Vaccination immunotherapy-an update. Scand J Surg 93:163–169PubMed
11.
Zurück zum Zitat Dutcher JP, Fine JP, Krigel RL, Murphy BA, Schaefer PL, Ernstoff MS, Loehrer PJ (2003) Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol 20:271–281CrossRefPubMed Dutcher JP, Fine JP, Krigel RL, Murphy BA, Schaefer PL, Ernstoff MS, Loehrer PJ (2003) Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol 20:271–281CrossRefPubMed
12.
Zurück zum Zitat Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076CrossRefPubMed Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076CrossRefPubMed
13.
Zurück zum Zitat Fossa SD, Mickisch GH, De Mulder PH, Horenblas S, van Oosterom AT, van Poppel H, Fey M et al. (2004) Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 101:533–540CrossRefPubMed Fossa SD, Mickisch GH, De Mulder PH, Horenblas S, van Oosterom AT, van Poppel H, Fey M et al. (2004) Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 101:533–540CrossRefPubMed
14.
Zurück zum Zitat Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarosa M et al. (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 77:2560–2566CrossRefPubMed Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarosa M et al. (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 77:2560–2566CrossRefPubMed
15.
Zurück zum Zitat Giannopoulos A, Constantinides C, Fokaeas E (2003) The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. Clin Cancer Res 15:5550–5558 Giannopoulos A, Constantinides C, Fokaeas E (2003) The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. Clin Cancer Res 15:5550–5558
16.
Zurück zum Zitat Gleave M, Elhilali MM, Fradet Y, Davis I, Venner P, Saad F, Klotz LH et al. (1998) Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 338:1265–1271CrossRefPubMed Gleave M, Elhilali MM, Fradet Y, Davis I, Venner P, Saad F, Klotz LH et al. (1998) Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 338:1265–1271CrossRefPubMed
17.
Zurück zum Zitat Huland E, Burger A, Fleischer J, Fornara P, Hatzmann E, Heidenreich A, Heinzer H et al. (2003) Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study. Folia Biol (Praha) 49:183–190 Huland E, Burger A, Fleischer J, Fornara P, Hatzmann E, Heidenreich A, Heinzer H et al. (2003) Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study. Folia Biol (Praha) 49:183–190
18.
Zurück zum Zitat Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ et al.; American Cancer Society (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29PubMed Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ et al.; American Cancer Society (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29PubMed
19.
Zurück zum Zitat Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E et al. (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363:594–599CrossRefPubMed Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E et al. (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363:594–599CrossRefPubMed
20.
Zurück zum Zitat Jurincic-Winkler CD, Metz KA, Beuth J, Klippel KF (2000) Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study. Eur Urol 37:45–49CrossRefPubMed Jurincic-Winkler CD, Metz KA, Beuth J, Klippel KF (2000) Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study. Eur Urol 37:45–49CrossRefPubMed
21.
Zurück zum Zitat Kälble T, Mohring K, Ikinger U et al. (1991) Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study. Urologe A 30:118–121PubMed Kälble T, Mohring K, Ikinger U et al. (1991) Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study. Urologe A 30:118–121PubMed
22.
Zurück zum Zitat Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG et al. (2004) Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100:2125–2131CrossRefPubMed Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG et al. (2004) Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100:2125–2131CrossRefPubMed
23.
Zurück zum Zitat Loskog A, Dzojic H, Vikman S et al. (2004) Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor. J Immunol 172:7200–7205PubMed Loskog A, Dzojic H, Vikman S et al. (2004) Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor. J Immunol 172:7200–7205PubMed
24.
Zurück zum Zitat Malmstrom PU (2002) A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int 89:681–686CrossRefPubMed Malmstrom PU (2002) A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int 89:681–686CrossRefPubMed
25.
Zurück zum Zitat McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133–141CrossRefPubMed McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133–141CrossRefPubMed
26.
Zurück zum Zitat Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE et al.; Eastern Cooperative Oncology Group/Intergroup trial (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21:1214–1222CrossRefPubMed Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE et al.; Eastern Cooperative Oncology Group/Intergroup trial (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21:1214–1222CrossRefPubMed
27.
Zurück zum Zitat Morales A, Chin JL, Ramsey EW (2001) Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 166:1633–1637CrossRefPubMed Morales A, Chin JL, Ramsey EW (2001) Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 166:1633–1637CrossRefPubMed
28.
Zurück zum Zitat Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P et al. (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972–2980PubMed Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P et al. (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972–2980PubMed
29.
Zurück zum Zitat Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J et al. (2002) Phase II trial of thalidomide for patients with advanced renal carcinoma. J Clin Oncol 20:302–306CrossRefPubMed Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J et al. (2002) Phase II trial of thalidomide for patients with advanced renal carcinoma. J Clin Oncol 20:302–306CrossRefPubMed
30.
Zurück zum Zitat Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, Muss H et al. (2003) Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21:99–101CrossRefPubMed Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, Muss H et al. (2003) Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21:99–101CrossRefPubMed
31.
Zurück zum Zitat Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM et al. (1999a) Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate. 39:54–59 Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM et al. (1999a) Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate. 39:54–59
32.
Zurück zum Zitat Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M et al. (1999b) Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38:73–78CrossRefPubMed Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M et al. (1999b) Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38:73–78CrossRefPubMed
33.
Zurück zum Zitat Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH (2003) Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 170:S84-S88CrossRefPubMed Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH (2003) Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 170:S84-S88CrossRefPubMed
34.
Zurück zum Zitat Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 338:1272–1278CrossRefPubMed Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 338:1272–1278CrossRefPubMed
35.
Zurück zum Zitat Negrier S, Caty A, Lesimple T, Douillard J-Y, Escudier B, Rossi J-F, Viens P et al. (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 18:4009–4015PubMed Negrier S, Caty A, Lesimple T, Douillard J-Y, Escudier B, Rossi J-F, Viens P et al. (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 18:4009–4015PubMed
36.
Zurück zum Zitat Nishiyama T, Tachibana M, Horiguchi Y et al. (2001) Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 7:23–31PubMed Nishiyama T, Tachibana M, Horiguchi Y et al. (2001) Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 7:23–31PubMed
37.
Zurück zum Zitat O’Donnell MA, Lilli K, Leopold C; National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group (2004) Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172:888–893CrossRefPubMed O’Donnell MA, Lilli K, Leopold C; National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group (2004) Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172:888–893CrossRefPubMed
38.
Zurück zum Zitat Pages F, Lebel-Binay S, Vieillefond A et al. (2002) Local immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer. Clin Exp Immunol 127:303–309CrossRefPubMed Pages F, Lebel-Binay S, Vieillefond A et al. (2002) Local immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer. Clin Exp Immunol 127:303–309CrossRefPubMed
39.
Zurück zum Zitat Papatsoris AG, Deliveliotis C, Giannopoulos A, Dimopoulos C (2004) Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study. Urol Int 72:284–291CrossRefPubMed Papatsoris AG, Deliveliotis C, Giannopoulos A, Dimopoulos C (2004) Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study. Urol Int 72:284–291CrossRefPubMed
40.
Zurück zum Zitat Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G et al. (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19:425–431PubMed Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G et al. (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19:425–431PubMed
41.
Zurück zum Zitat Pound CR, Partin AW, Eisenberger MA et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Ass 281:1591–1597CrossRef Pound CR, Partin AW, Eisenberger MA et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Ass 281:1591–1597CrossRef
42.
Zurück zum Zitat Ragde H, Cavanagh WA, Tjoa BA (2004) Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 172:2532–2538CrossRefPubMed Ragde H, Cavanagh WA, Tjoa BA (2004) Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 172:2532–2538CrossRefPubMed
43.
Zurück zum Zitat Rajala P, Kaasinen E, Raitanen M et al. (2002) Perioperative single dose instillation of epirubicin or interferon alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomised multicenter study-FinnBladder long-term results. J Urol 168:981–985CrossRefPubMed Rajala P, Kaasinen E, Raitanen M et al. (2002) Perioperative single dose instillation of epirubicin or interferon alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomised multicenter study-FinnBladder long-term results. J Urol 168:981–985CrossRefPubMed
44.
Zurück zum Zitat Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R et al. (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003–3015CrossRefPubMed Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R et al. (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003–3015CrossRefPubMed
45.
Zurück zum Zitat Sarosdy MF, Lowe BA, Schellhammer PF et al. (1996) Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 48:21–27CrossRefPubMed Sarosdy MF, Lowe BA, Schellhammer PF et al. (1996) Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 48:21–27CrossRefPubMed
46.
Zurück zum Zitat Shelley MD, Kynaston H, Court J et al. (2001) A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88:209–216CrossRefPubMed Shelley MD, Kynaston H, Court J et al. (2001) A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88:209–216CrossRefPubMed
47.
Zurück zum Zitat Stravoravdi P, Toliou T, Kirtsis P et al. (1999) A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa. J Interferon Cytokine Res 19:221–225CrossRefPubMed Stravoravdi P, Toliou T, Kirtsis P et al. (1999) A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa. J Interferon Cytokine Res 19:221–225CrossRefPubMed
48.
Zurück zum Zitat Swindle PW, Tepes S, Clements J (2004) DC therapy for prostate cancer. Cytotherapy 6:164–171CrossRefPubMed Swindle PW, Tepes S, Clements J (2004) DC therapy for prostate cancer. Cytotherapy 6:164–171CrossRefPubMed
49.
Zurück zum Zitat Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964–1970CrossRefPubMed Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964–1970CrossRefPubMed
50.
Zurück zum Zitat Varga Z, de Mulder P, Kruit W, Hegele A, Hofmann R, Lamers C, Warnaar S et al. (2003) A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients. Folia Biol (Praha) 49:74–77 Varga Z, de Mulder P, Kruit W, Hegele A, Hofmann R, Lamers C, Warnaar S et al. (2003) A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients. Folia Biol (Praha) 49:74–77
51.
Zurück zum Zitat Weiss GR, O’Donnell MA, Loughlin K et al. (2003) Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder J Immunother 26:343–348 Weiss GR, O’Donnell MA, Loughlin K et al. (2003) Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder J Immunother 26:343–348
52.
Zurück zum Zitat Witjes WP, Konig M, Boeminghaus FP et al.; Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur Urol 36:576–581 Witjes WP, Konig M, Boeminghaus FP et al.; Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur Urol 36:576–581
53.
Zurück zum Zitat Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA et al. (2003a) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127–3132CrossRefPubMed Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA et al. (2003a) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127–3132CrossRefPubMed
54.
Zurück zum Zitat Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM et al. (2003b) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434CrossRefPubMed Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM et al. (2003b) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434CrossRefPubMed
55.
Zurück zum Zitat Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M et al. (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60:332–337CrossRefPubMed Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M et al. (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60:332–337CrossRefPubMed
56.
Zurück zum Zitat Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB et al. (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20:4559–4566CrossRefPubMed Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB et al. (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20:4559–4566CrossRefPubMed
Metadaten
Titel
Immuntherapie urologischer Tumoren
verfasst von
Dr. C. Doehn
I. Kausch
D. Jocham
Publikationsdatum
01.05.2005
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 5/2005
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-005-0876-7

Weitere Artikel der Ausgabe 5/2005

Der Onkologe 5/2005 Zur Ausgabe

Neu im Fachgebiet Onkologie

Muskeln trainieren gegen Nervenschäden durch Chemotherapie

17.07.2024 Nebenwirkungen der Krebstherapie Nachrichten

Chemotherapien können die Nerven schädigen und damit die Lebensqualität von Betroffenen zusätzlich einschränken. Wer aber auf die richtige Art trainiert, kann das absolute Risiko für Neuropathien um bis zu 40% senken.

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen. Patienten mit fortgeschrittenem nichtkleinzelligem Lungenkarzinom etwa hatten das beste Outcome, wenn die PD-1-Inhibitor-Infusionen in den Wintermonaten starteten.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.